An open-label phase III study to assess the long term safetly profile of GW433908 containing regimens in HIV-1 infected subjects.

Trial Profile

An open-label phase III study to assess the long term safetly profile of GW433908 containing regimens in HIV-1 infected subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2013

At a glance

  • Drugs Fosamprenavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jul 2011 Actual end date (October 2010) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top